WO2002012339A3 - Sequences for integrin alpha-8 - Google Patents

Sequences for integrin alpha-8 Download PDF

Info

Publication number
WO2002012339A3
WO2002012339A3 PCT/US2001/024148 US0124148W WO0212339A3 WO 2002012339 A3 WO2002012339 A3 WO 2002012339A3 US 0124148 W US0124148 W US 0124148W WO 0212339 A3 WO0212339 A3 WO 0212339A3
Authority
WO
WIPO (PCT)
Prior art keywords
intg
sequences
integrin alpha
provides
polynucleotides
Prior art date
Application number
PCT/US2001/024148
Other languages
French (fr)
Other versions
WO2002012339A2 (en
Inventor
Ernestine A Lee
Li Ding
Kavitha Thangavelu
Original Assignee
Incyte Genomics Inc
Ernestine A Lee
Li Ding
Kavitha Thangavelu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Ernestine A Lee, Li Ding, Kavitha Thangavelu filed Critical Incyte Genomics Inc
Priority to CA002417676A priority Critical patent/CA2417676A1/en
Priority to EP01957374A priority patent/EP1305340A2/en
Priority to AU2001279128A priority patent/AU2001279128A1/en
Priority to JP2002518310A priority patent/JP2004510415A/en
Publication of WO2002012339A2 publication Critical patent/WO2002012339A2/en
Publication of WO2002012339A3 publication Critical patent/WO2002012339A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides human integrins (INTG) and polynucleotides which identify and encode INTG. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of INTG.
PCT/US2001/024148 2000-08-03 2001-08-01 Sequences for integrin alpha-8 WO2002012339A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002417676A CA2417676A1 (en) 2000-08-03 2001-08-01 Sequences for integrin alpha-8
EP01957374A EP1305340A2 (en) 2000-08-03 2001-08-01 Sequences for integrin alpha-8
AU2001279128A AU2001279128A1 (en) 2000-08-03 2001-08-01 Integrins
JP2002518310A JP2004510415A (en) 2000-08-03 2001-08-01 Integrin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22327000P 2000-08-03 2000-08-03
US60/223,270 2000-08-03

Publications (2)

Publication Number Publication Date
WO2002012339A2 WO2002012339A2 (en) 2002-02-14
WO2002012339A3 true WO2002012339A3 (en) 2002-06-13

Family

ID=22835780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024148 WO2002012339A2 (en) 2000-08-03 2001-08-01 Sequences for integrin alpha-8

Country Status (5)

Country Link
EP (1) EP1305340A2 (en)
JP (1) JP2004510415A (en)
AU (1) AU2001279128A1 (en)
CA (1) CA2417676A1 (en)
WO (1) WO2002012339A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854658A1 (en) * 2011-11-09 2013-05-16 Aestus Therapeutics, Inc. Methods of treating schizophrenia with phenylalanine enamide derivative inhibitors of .alpha.4 integrin possessing a cyclobutene group

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] Hinxton, UK; 22 October 2001 (2001-10-22), TANG ET AL.: "Human polynucleotide SEQ ID NO 4172", XP002192322, Database accession no. AAI60183 *
DATABASE EBI [online] Hinxton, UK; 22 October 2001 (2001-10-22), TANG ET AL.: "Human polypeptide SEQ ID: 2386", XP002192255, Database accession no. AAM39241 *
DATABASE EBI [online] Hinxton, UK; 22 October 2001 (2001-10-22), TANG ET AL.: "Humna Polypeptide SEQ ID NO 5958", XP002192254, Database accession no. AAM41027 *
DATABASE EBI [online] Hinxton, UK; 22 October 2001 (2001-10-22), TANG ET AL: "Human polynucleotide SEQ ID NO 600", XP002192253, Database accession no. AAI58397 *
DATABASE EBI Hinxton, UK; YOUNG ET AL.: "Sequence 7924", XP002192256 *
MUELLER ULRICH ET AL: "Integrin alpha-8-beta-1 is critically important for epithelial-mesenchymal interactions during kidney morphogenesis.", CELL, vol. 88, no. 5, 1997, pages 603 - 613, XP002192236, ISSN: 0092-8674 *
SCHNAPP LYNN M ET AL: "Sequence and tissue distribution of the human integrin alpha-8 subunit: A beta-1-associated alpha subunit expressed in smooth muscle cells.", JOURNAL OF CELL SCIENCE, vol. 108, no. 2, 1995, pages 537 - 544, XP002192235, ISSN: 0021-9533 *

Also Published As

Publication number Publication date
WO2002012339A2 (en) 2002-02-14
CA2417676A1 (en) 2002-02-14
JP2004510415A (en) 2004-04-08
EP1305340A2 (en) 2003-05-02
AU2001279128A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2001098468A3 (en) Proteases
WO2002008396A3 (en) Human proteases
WO2001098354A3 (en) Human receptors
WO2001051638A3 (en) Drug metabolizing enzymes
WO2001090334A3 (en) Drug metabolizing enzymes
WO2002004612A3 (en) Drug metabolizing enzymes
WO2002038744A3 (en) Proteases
WO2002026950A3 (en) Transferases
WO2001098471A3 (en) Human phosphodiesterases
WO2001096546A3 (en) Protein phosphatases
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2001071004A3 (en) Proteases
WO2002010363A3 (en) Protein phosphatases
WO2002101009A3 (en) Structural and cytoskeleton-associated proteins
WO2002020736A3 (en) Proteases
WO2002024924A3 (en) Protein phosphatases
WO2002053719A3 (en) Cytoskeleton-associated proteins
WO2001059127A3 (en) Drug metabolizing enzymes
WO2001079468A3 (en) Drug metabolizing enzymes
WO2002026998A3 (en) Hydrolases
WO2001055358A3 (en) Phosphodiesterases
WO2001046443A3 (en) Proteases
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2002012467A3 (en) Drug metabolizing enzymes
WO2001092527A3 (en) Regulators of apoptosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2417676

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002518310

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001957374

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001957374

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001957374

Country of ref document: EP